Clinical Trial

Periprostatic Neurolysis in Prostate Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to assess whether inhibiting nerve activity to the prostate delays progression of disease in men with high-risk clinical features for prostate cancer. Prostate cancer has been shown to invade nerves, a mechanism that is thought to be involved in prostate cancer spread in men with high-risk cancer. When nerve activity to the prostate is blocked in mice with prostate cancer, prostate cancer growth and spread are inhibited. In a previous study we showed that doing so in humans was safe and may have anticancer therapeutic effect. In this study we will test whether one versus two injections of nerve blocking agent is more effective at reducing nerves in the prostate and whether it will slow/stop spread of prostate cancer after treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-27; most recent amendment 2026-07-14.
Status change: Recruiting → Active, Not Recruiting 2026-07-14
Status change: Not Yet Recruiting → Recruiting 2025-08-24
Trial Details
NCT Number NCT07100847
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: Urology Care Foundation, American Urological Association
Conditions PROSTATE CANCER, NERVES, NEUROBIOLOGY OF CANCER, NEUROLYSIS
Enrollment 21 participants
Start Date 2025-08-15
Primary Completion 2026-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-16